Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment tags : Phase 1 save search
FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder
Published: 2023-03-22 (Crawled : 13:00) - biospace.com/
HUGE | $0.6167 1.22% 29K
|
Process Industries
|
| O: 0.65%
H: 3.21%
C: 0.0%
pharma candidate approval treatment trial potential phase 1 major depressive disorder
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1
Published: 2023-03-20 (Crawled : 23:00) - biospace.com/
FUSN | $21.24 0.0% 330K
|
Health Technology
|
| O: -2.17%
H: 3.69%
C: -1.48%
fpi-2059 tumors treatment pharmaceuticals therapy study phase 1
Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial
Published: 2023-03-16 (Crawled : 13:00) - globenewswire.com
DERM | $3.54 -8.29% -9.04% 190K
|
|
| O: -4.96%
H: 15.3%
C: 10.07%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 2.54%
H: 0.0%
C: 0.0%
dfd-29 corporation treatment impact medical trial phase 1
Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes
Published: 2023-03-08 (Crawled : 13:00) - biospace.com/
SEOVF | $0.3284 15.67% 2K
|
Health Technology
|
| O: 1.27%
H: 4.0%
C: -2.5%
treatment trial diabetes phase 1
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
Published: 2023-02-28 (Crawled : 14:00) - biospace.com/
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: -0.46%
H: 2.06%
C: -0.46%
treatment ongoing study phase 1
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema
Published: 2023-02-27 (Crawled : 23:00) - globenewswire.com
OCGN | News A | $1.315 -8.68% -9.51% 8M
|
Health Technology
|
| O: -0.06%
H: 5.6%
C: 2.13%
ocu200 treatment fda drug macular application trial submission diabetic phase 1
Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1
Published: 2023-02-22 (Crawled : 15:00) - biospace.com/
DARE | $0.299 5.77% 5.45% 970K
|
Health Technology
|
| O: 0.93%
H: 4.59%
C: -1.83%
treatment potential bioscience study phase 1
BioNova Announces First Patient Dosed in a Phase 1/2 Study of BN301 for the Treatment of Hematologic Malignancies in China
Published: 2023-02-13 (Crawled : 17:00) - sutrobio.com
STRO M | $3.76 -1.05% -1.06% 770K
|
Health Technology
|
| O: -0.31%
H: 8.62%
C: -1.88%
bn301 treatment china study phase 1
Moleculin Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
Published: 2023-02-13 (Crawled : 13:20) - prnewswire.com
MBRX | News | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: 5.82%
H: 4.84%
C: -4.84%
treatment topline leukemia trial phase 1
Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD
Published: 2023-02-11 (Crawled : 16:20) - globenewswire.com
OCUL | News | $5.86 -22.69% -29.35% 6.1M
|
Health Technology
| Email alert
Add to watchlist
treatment ongoing ocular trial phase 1
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
Published: 2023-02-02 (Crawled : 13:00) - biospace.com/
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: 1.3%
H: 3.52%
C: 3.52%
treatment fibrosis pharmaceuticals study phase 1
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
Published: 2023-01-31 (Crawled : 23:00) - biospace.com/
PRTA 4 | $20.6 -1.91% -1.94% 570K
|
Health Technology
|
| O: 0.58%
H: 2.79%
C: 2.3%
prx005 treatment disease topline antibody alzheimer’s potential study phase 1
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
Published: 2023-01-12 (Crawled : 13:20) - globenewswire.com
ADXS | $0.6455 12.48% 2.3K
|
Health Technology
|
| O: 10.0%
H: 7.27%
C: -3.03%
adxs-504 treatment trial cancer prostate cancer phase 1
Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 TrialA Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options
Published: 2023-01-05 (Crawled : 17:00) - biospace.com/
OVID | $3.23 3.86% 3.72% 230K
|
Health Technology
|
| O: -1.05%
H: 2.13%
C: 2.13%
ov329 treatment rare therapeutics phase 1
Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Published: 2022-12-21 (Crawled : 14:00) - biospace.com/
MBRX | News | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: -1.52%
H: 0.18%
C: -3.85%
treatment leukemia trial approval acute myeloid leukemia aml phase 1
Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022
Published: 2022-12-12 (Crawled : 12:20) - prnewswire.com
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: -18.74%
presentation phase 1
Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Published: 2022-12-08 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.26%
H: 2.62%
C: 0.37%
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: 0.85%
H: 0.6%
C: -4.77%
hzn-457 treatment trial phase 1
Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Published: 2022-12-08 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.26%
H: 2.62%
C: 0.37%
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: 0.85%
H: 0.6%
C: -4.77%
hzn-457 treatment trial therapeutics phase 1
Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
Published: 2022-12-01 (Crawled : 13:20) - globenewswire.com
SLRX A | $0.5105 -2.88% 8.8K
|
Commercial Services
|
| O: 1.04%
H: 1.79%
C: -6.15%
treatment pharmaceuticals seclidemstat trial phase 1
Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
Published: 2022-11-17 (Crawled : 14:00) - biospace.com/
COCP | $1.43 -1.39% 5.1K
|
Health Technology
|
| O: 2.67%
H: 1.3%
C: -2.92%
cc-4234 treatment pharma antiviral influenza study cc-42344 phase 1
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.